FDA grants emergency authorisation for bamlanivimab for high-risk COVID-19 patients

Bamlanivimab, a monoclonal antibody, is now available under emergency use in the US for the treatment of mild to moderate COVID-19 in adults and paediatric patients 12 years and older who are at high risk of progressing to severe COVID-19 and/or hospitalisation.

Source:

PharmaTimes